Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Perry D. Haaland is active.

Publication


Featured researches published by Perry D. Haaland.


Journal of Immunological Methods | 2003

Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses—potential clinical implications

Rakesh Sindhi; Jan Allaert; Daiva Gladding; Perry D. Haaland; Bruce Koppelman; John F. Dunne; Suren N. Sehgal

BACKGROUND In mitogen-stimulated lymphocyte responses (sLR), cytokines and cell-surface receptors in peripheral human blood lymphocytes (PBL) are sensitive to cyclosporine (CsA), and can predict its in vivo effect with pharmacodynamic (PD) modeling. This is not known for multiple-agent combinations. METHODS Twenty-five concentration mixtures of CsA (0-1200 ng/ml) plus sirolimus (SRL, 0-30 ng/ml) were added to whole blood from five normal human subjects (NHS) for effect on a limited array of six targets. Effect-concentration relationships were analyzed with E(max) PD equations, and expressed as the range of concentration mixtures associated with one-half of maximal inhibitory effect (EC(50)) on a model biomarker target. This predicted range was examined to see whether it contained representative concentration mixtures of these two drugs, which were associated with a stable post-transplant outcome in a logistic regression model of 1039 clinical trial patients. RESULTS PD analyses suggested that in NHS samples containing CsA+SRL (n=5), (1) PMA-Ionomycin-stimulated T-cell expression of intracellular IL-2, TNF-alpha, and IFN-gamma was inhibited by CsA, and minimally by SRL, and (2) the two agents inhibited pokeweed mitogen (PWM)-stimulated B-cell expression of CD54 and CD95, but not CD86 (ICAM-1, Fas antigen, and B7.2), synergistically. With CD54 as the model biomarker, contour plots also predicted a wide range of concentration mixtures of the two agents across which an EC(50) could be predicted for CsA+SRL in a population (e.g., CsA-72 ng/ml+SRL 15 ng/ml, n=5), as well as in the individual subject (e.g., CsA-0 ng/ml+SRL-13.75 ng/ml in NHS-D310). Logistic regression analysis of clinical outcomes in 1039 patients suggested that the concentration mixture of CsA congruent with 50-150 ng/ml+SRL congruent with 10 ng/ml was associated with a stable post-transplant course. The EC(50) contour plot for CD54 suggested a nearly identical CsA concentration of 120 ng/ml in the presence of 10 ng/ml of sirolimus. CONCLUSIONS Our data suggest that pharmacodynamic evaluation of immunosuppressive agents with biomarkers may be an efficient process with which to characterize immunosuppressive effect of combination agents in individual patients and in patient populations.


Archive | 2003

Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells

Sharon C. Presnell; Mohammad A. Heidaran; Perry D. Haaland


Archive | 2005

Cell culture environments for the serum-free expansion of mesenchymal stem cells

Chang Chen; Andrea Liebmann-Vinson; Ruiling Xu; Jonathon Allen Rowley; Perry D. Haaland; Bryce Chaney; Matthew Mitchell


Archive | 1997

Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples

Perry D. Haaland


Archive | 1999

Methods, apparatus and computer program products for determining quantities of nucleic acid sequences in samples using standard curves and amplification ratio estimates

Perry D. Haaland; James G. Nadeau; Colleen M. Nycz; Cheryl H. Dean; Catherine A. Spargo


Omics A Journal of Integrative Biology | 2006

Data standards for flow cytometry.

Josef Spidlen; Robert Gentleman; Perry D. Haaland; Morgan Langille; Nolwenn Le Meur; Michael F. Ochs; Charles Schmitt; Clayton A. Smith; Adam S. Treister; Ryan R. Brinkman


Archive | 2006

Peptides promoting cell adherence, growth and secretion

Robert L. Campbell; Mohammad A. Heidaran; Catherine A. Spargo; Jamie H. Wilkins; Perry D. Haaland


Archive | 1999

Computerized method and apparatus for analyzing nucleic acid assay readings

Harry Yang; Daniel L. Schwarz; Christopher M. Embres; Richard Moore; Perry D. Haaland; Paula V. Johnson


Archive | 2004

Peptides for use in culture media

Perry D. Haaland; Douglas B. Sherman; Robert L. Campbell; Walter William Stewart; Sheila Ann Lloyd; Bruce Wayne Erickson


Archive | 2005

Automated media optimization technology

Perry D. Haaland; Bryce Chaney; Stacy Holdread

Collaboration


Dive into the Perry D. Haaland's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge